

25 February 2026

U.S. Provisional Patent for Novel NanoBodies Platform Targeting Septic Shock and Systemic Inflammation

Highlights:

- **Provisional patent application filed with the USPTO for the NanoBodies (NB) platform (Application No. 63/979,136)**
- **NanoBodies programme targets vascular and peptide-mediated mechanisms implicated in septic shock and systemic inflammatory disorders**
- **Expands the Company's immune-modulatory portfolio beyond cytokine regulation into upstream signalling control**

Argent BioPharma Ltd (ASX: RGT) (Argent or the Company) is pleased to provide an update on the advancement of its internal NanoBodies (NB) research programme and related intellectual property development.


The Company has successfully filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for its NanoBodies platform under Application No. 63/979,136. The filing secures priority protection for the platform's designated peptide targets and associated nanobody constructs, initiating a 12-month period to further develop and substantiate the intellectual property.

NanoBodies, also known as single-domain antibodies, are compact and highly specific binding molecules that offer structural stability and enhanced tissue accessibility compared to conventional antibody formats. Their small molecular size and physicochemical resilience make them suitable for targeting complex signalling pathways involved in immune and inflammatory processes.

The NanoBodies programme is strategically focused on vascular and peptide-mediated signalling mechanisms implicated in septic shock and related systemic inflammatory disorders. Proof-of-concept studies are planned using a cecal ligation and perforation (CLP) septic shock model, a widely accepted translational preclinical model for human septic shock. This model enables evaluation of vascular stability, immune modulation, and inflammatory biomarker responses, including IL-6 and TNF- α .

This initiative complements the Company's existing immune-focused pipeline. While CimetrA® primarily modulates inflammatory cytokine pathways and immune overactivation, the NanoBodies platform is designed to explore upstream vascular and peptide signalling mechanisms involved in inflammatory progression. Together, these programmes reinforce Argent BioPharma's integrated Neuro-Immune strategy, addressing inflammation across multiple regulatory levels. Commercial Milestone

The NanoBodies initiative strengthens the scientific breadth of the Company's immune-modulatory portfolio and enhances its long-term U.S.-centred intellectual property position across inflammatory and immune-mediated indications.



Roby Zomer, CEO & Managing Director, commented:

“The filing of our NanoBodies provisional patent represents a strategic expansion of Argent BioPharma’s immune-focused platform. By targeting upstream vascular and peptide-mediated mechanisms, we are broadening our scientific approach beyond cytokine modulation and reinforcing the structural depth of our pipeline. This initiative strengthens our internal R&D capability and adds long-term intellectual property value as we continue advancing our neuro-immune strategy.”

Amir Polak, Chief Pharma Development Officer, commented:

“The NanoBodies programme reflects a scientifically differentiated approach to immune modulation. By focusing on peptide-mediated and vascular-dynamic signalling pathways, we are investigating mechanisms that sit upstream of cytokine activation, which may offer additional therapeutic leverage in acute inflammatory conditions such as septic shock. The planned CLP translational model will allow us to systematically evaluate biomarker responses and vascular stability in a controlled preclinical setting.”

—Ends—

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma

Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma

Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

About Argent BioPharma

Argent BioPharma Ltd. (ASX: RGT) is a revenue-generating, clinical-stage biopharmaceutical company focused on the development and commercialisation of nano-engineered therapeutics targeting neurological and immune-mediated disorders. Its lead assets, CannEpi[®] and CimetrA[®], are being advanced for drug-resistant epilepsy and inflammatory conditions, respectively. The Company leverages proprietary nano-delivery technologies designed to optimise bioavailability and tissue penetration, including across the blood–brain barrier and pulmonary interfaces. With vertically integrated EU-GMP manufacturing, a unified Neuro-Immune Modulatory platform, and ongoing clinical development programs, Argent BioPharma is advancing a focused pipeline targeting central nervous system and systemic inflammatory conditions with significant unmet medical need

Follow us through our social media channels:

LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma

